We are a leading healthcare campus encompassing all fields of health: from healthcare and research to teaching and management.
Professionalism, commitment and research by professionals on the Campus are the key elements in offering patients excellent care.
We are committed to research as a tool to provide solutions to the daily challenges we face in the field of medical healthcare.
Thanks to our healthcare, teaching and research potential, we work to incorporate new knowledge to generate value for patients, professionals and the organization itself.
We generate, transform and transmit knowledge in all areas of the health sciences, helping to train the professionals of the future.
We are defined by our vocation for communication. We invite you to share everything that happens at Vall d'Hebron Barcelona Hospital Campus, and our doors are always open.
Hospital donations
Research donations
Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.
The Esperanza Nacional Award for Research in Multiple Sclerosis granted by the Multiple Sclerosis Association of Toledo (ADEMTO) aims to promote and recognize the research carried out by national research groups in the field of multiple sclerosis. This year, the third edition of the award has recognized a work led by researchers from Cemcat, Vall d'Hebron University Hospital and Vall d'Hebron Research Institute (VHIR).
The study, published in 2022 in the journal Brain, analyzes the levels of free kappa light chains in cerebrospinal fluid and concludes that their accuracy in diagnosing new cases of multiple sclerosis is slightly higher than that of oligoclonal bands, the biomarker currently included in the diagnostic criteria for the disease. "Both types of proteins are associated with inflammatory processes", explains Dr. Carmen Espejo, principal investigator at Cemcat and the Clinical Neuroimmunology group at VHIR, and first author of the study, together with Dr. Georgina Arrambide, neurologist and researcher at Cemcat and the Clinical Neuroimmunology group at VHIR.
"Our results show that determining the kappa free light chain index is a fast, cost-effective and readily available alternative when it is not possible to assess the presence of oligoclonal bands," the researcher says. "Therefore, we propose to modify the current diagnostic criteria, the McDonald 2017 criteria, so that either biomarker can be used to diagnose the disease."
Dr. Espejo collected the award on Monday, December 18 at ADEMTO headquarters in Toledo. "We are very grateful, as the award is a recognition of our research and a motivation to continue advancing in the knowledge of multiple sclerosis."
The study has proven the efficacy of a new biomarker to diagnose MS
Clinical neuroimmunology, General Hospital
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.